News Astellas suffers pancreatic cancer failure with Vyloy Astellas' effort to expand the reach of its first-in-class claudin 18.2 drug Vyloy into pancreatic cancer has had a major setback.
News WHO sounds alarm over rising tide of antibiotic resistance One in six common bacterial infections in people worldwide in 2023 were resistant to antibiotic treatments, according to the WHO.
News UCB drug for rare disease TK2d boosts survival UCB's experimental medicine for TK2d, currently under regulatory review, offers hope to patients with the devastating rare disease.
News BMS builds in 'in vivo' cell therapy with $1.5bn Orbital buy Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics, a developer of in vivo cell therapies, for $1.5bn in cash.
News Soufflé's tasty $200m raise, and other biofinancings New biotech financings include nine-figure rounds for Soufflé, Expedition, Arthrosi, and Nilo Therapeutics, with NanoPhoria and TORL not far behind.
News In monster MASH takeover deal, Novo buys Akero for $4.7bn Novo Nordisk has agreed to buy Akero and its MASH drug efruxifermin for $4.7bn upfront, soon after Wegovy was approved for the common liver disease.
Oncology ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o... For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
